Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Vetoquinol SA is a France-based veterinary pharmaceutical company specializing in the research, development, production, and marketing of innovative veterinary drugs and non-medicinal care products. Founded in 1933 and headquartered in Lure, it operates as an independent, family-owned business dedicated to enhancing animal health and well-being for companion animals like dogs and cats, as well as livestock including cattle, pigs, sheep, poultry, and horses. Its product portfolio covers key therapeutic areas such as mobility, pain and inflammation management; dermatology, hygiene, and care; anti-parasitics; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology. In 2025, Vetoquinol SA achieved sales revenue of €526 million, with 70% from companion animals and 30% from farm animals, supported by subsidiaries in 24 countries and a network of over 60 distributors reaching approximately 100 countries worldwide. Employing around 2,500 people, the company emphasizes geographical diversification, strategic acquisitions, and close partnerships with veterinarians, farmers, and pet owners to deliver customized solutions. Vetoquinol SA plays a significant role in the global animal health market as one of the top international players, fostering innovation for a better planet.
14.97% operating margin is respectable but not wide. ROIC at 9.34%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 2.5% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 25% versus the prior year, cash generation momentum has weakened.
Profitability & Returns
Revenue (TTM)
€526M
▼ -2.5% YoY
Net Income (TTM)
€57M
▼ -2.3% YoY
Op. Margin
14.97%
▲ +0.8pp YoY
ROIC
9.34%
▼ -0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€51M
▼ -24.7% YoY
Op. Cash Flow (TTM)
€54M
▼ -33.1% YoY
Net Debt
-€206M
Net Cash Position
Cash & Equiv.
€221M
3Y CAGR: -0.9%
3Y CAGR: +8.4%
Continue Research